What type of study is this?

This is a In Vitro Study study.

FADS3 fuels CcRCC progression via lipid-droplet/TGF-β receptors axis bridging metabolic reprogramming and epithelial plasticity

View Full Paper

Ask AI

Bookmark

Authors

Analysis shows FADS3 enhances cell proliferation in ccRCC, indicating potential biomarker for tumor progression and prognosis.

Tumor progression is linked to elevated fads3 levels, driving metabolic reprogramming and epithelial-mesenchymal transition.
Analysis found that fads3 promotes cell proliferation and sunitinib resistance in clear cell renal cell carcinoma.
Utilizing multimodal technologies revealed fads3’s role in lipid droplet accumulation and fatty acid metabolism.
Enhancing fads3 may provide insights into metabolic pathways, leading to better prognostic biomarkers for ccRCC.

Bai et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark